Payment overview · 2025
General Payments
$79.32
4 reported records · 2 companies
Healthcare provider profile · identity verified
Whitney D Stacy, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ALICE, TX · NPI 1932444809
Verified facts
What the public records show
CMS Open Payments records show Whitney D Stacy, FNP-BC received $79.32 in general payments during 2025 across 4 reported records.
Merck Sharp & Dohme LLC accounted for 57.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.63 | 57.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.69 | 42.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.32 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.69 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.69 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 248 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
248 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 144 |
| Lisinopril | Lisinopril | 289 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 85 |
| Ozempic | Semaglutide | 248 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 69 |
| Gabapentin | Gabapentin | 207 | 53 |
| Simvastatin | Simvastatin | 185 | 58 |
| Tramadol Hcl | Tramadol Hcl | 185 | 55 |
| Metformin Hcl | Metformin Hcl | 178 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 41 |
| Mounjaro | Tirzepatide | 177 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 40 |
| Losartan Potassium | Losartan Potassium | 151 | 50 |
| Furosemide | Furosemide | 148 | 37 |
| Omeprazole | Omeprazole | 144 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 43 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 113 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 112 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 42 |
| Jardiance | Empagliflozin | 104 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 16 |
| Trazodone Hcl | Trazodone Hcl | 93 | 18 |
| Alendronate Sodium | Alendronate Sodium | 90 | 27 |
| Pregabalin | Pregabalin | 90 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 28 |
| Celecoxib | Celecoxib | 65 | 17 |
| Ezetimibe | Ezetimibe | 63 | 20 |
| Glipizide Er | Glipizide | 62 | 20 |
| Allopurinol | Allopurinol | 59 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Cefuroxime | Cefuroxime Axetil | 53 | 39 |
| Famotidine | Famotidine | 53 | 14 |
| Eliquis | Apixaban | 52 | suppressed |
| Glipizide | Glipizide | 51 | 19 |
| Ibuprofen | Ibuprofen | 48 | 22 |
| Baclofen | Baclofen | 47 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 15 |
| Myrbetriq | Mirabegron | 42 | 11 |
| Meloxicam | Meloxicam | 41 | 12 |
| Metformin Hcl Er | Metformin Hcl | 39 | 14 |
| Enalapril Maleate | Enalapril Maleate | 38 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Mupirocin | Mupirocin | 37 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 14 |
| Spironolactone | Spironolactone | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 12 |
| Potassium Chloride | Potassium Chloride | 32 | 11 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 14 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.32 · 4 records | Merck Sharp & Dohme LLC | CAPVAXIVE, Ozempic, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error